KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → (Kirsten rat sarcoma viral oncogene) mutationsA change in DNA sequence that can drive cancer development.Click for full explanation → drive the vast majority of pancreatic cancers, and KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation →-directed therapies represent the most significant investigational focus. A Phase 3 trial is studying daraxonrasib (a KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → inhibitor) alone and in combination with gemcitabine and nab-paclitaxel as first-line treatment in metastatic disease. A separate Phase 3 trial is evaluating setidegrasib, another KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation →-targeting agent, together with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → has had limited success in pancreatic cancer due to an immunosuppressive tumor microenvironment, but combinations continue to be explored. A Phase 2 trial is adding pembrolizumab to olaparib for patients with DNA repair gene alterations. Research from recent literature describes multi-epitope TGF-beta (transforming growth factor beta) vaccination rationale. A Phase 1 trial is examining a KISIMA-02 cancer vaccine combined with the checkpoint inhibitor ezabenlimab.
Novel cell therapies are in early evaluation. A Phase 1 trial is testing dual-targeting CAR-NK (chimeric antigen receptorA type of immunotherapy that genetically engineers a patient's own T cells to recognise and destroy cancer cells.Click for full explanation → natural killer) cells against mesothelin and MUC1. Fecal microbial transplants are being piloted in a Phase 1 study as a means to modulate the tumor immune environment.
Early detection remains a priority, with ongoing studies of serum biomarkerA measurable biological signal used to detect disease or predict treatment response.Click for full explanation → signatures and screening programs targeting high-risk individuals.
Where the evidence stands
FOLFIRINOX and gemcitabine plus nab-paclitaxel have Phase 3 evidence supporting their use as frontline regimens. Olaparib maintenance for BRCAGenes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →-mutated disease rests on Phase 3 data, though it applies to a small fraction of patients. KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → inhibitors represent the most advanced investigational category, with multiple Phase 3 trials now enrolling, marking a potential shift in treatment options. ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → combinations, cancer vaccines, and cellular therapies are at Phase 1 to Phase 2. Accurate early detection remains an unmet need, with biomarkerA measurable biological signal used to detect disease or predict treatment response.Click for full explanation → and screening research ongoing at early stages.
What this means for people affected
Pancreatic cancer treatment options remain more limited than many other cancers, but the field is advancing in meaningful ways. KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → inhibitors represent a particularly active area of development, targeting the mutationA change in DNA sequence that can drive cancer development.Click for full explanation → that drives most cases, and Phase 3 data are expected in coming years. For patients with BRCAGenes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →mutationsA change in DNA sequence that can drive cancer development.Click for full explanation →, targeted therapyDrugs that block specific molecules that cancer cells need to grow.Click for full explanation → has already proven useful. Identifying the disease earlier, when surgery is still an option, remains a key priority, with screening studies underway in high-risk groups.
Last updated April 2, 2026
Recent research findings
Understanding evidence levels▼
PreclinicalLab or cell studies — no human data yet.
Animal StudyResults in animals only — may not apply to humans.
Phase 1 TrialFirst-in-human safety testing in small groups.
Phase 2 TrialEarly effectiveness testing in a larger group.
Phase 3 TrialLarge controlled trial — the strongest trial evidence.
Observational StudyPatterns observed in populations — not a controlled trial.
ReviewSummary analysis of multiple existing studies.
Meta-AnalysisStatistical pooling of results from multiple studies.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 3, 2026
Researchers Identify Key Players in Pancreatic Cancer's Immune Evasion
Scientists studied pancreatic cancer's tumor environment and found that a protein called PAI1 helps cancer cells evade the immune system. They also discovered that another protein, tPA, has a role in fighting cancer. The researchers found that when they removed PAI1, the cancer grew faster, and when they removed tPA, the immune system's ability to fight cancer worsened.
Why it matters: This finding could help researchers develop new treatments to overcome pancreatic cancer's ability to evade the immune system.
This study was conducted in a lab setting and may not directly translate to human patients.
Phase 1 TrialFirst-in-human trial. Focuses on safety and dosing in small groups.Est. completion: June 1, 2028
Testing PTM-101 in Pancreatic Cancer Patients
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the safety and effects of PTM-101 in people with pancreatic ductal adenocarcinoma (PDAC). The trial is currently recruiting participants. The results of this trial are not yet known.
Why it matters: This trial may help researchers understand how PTM-101 works in treating pancreatic cancer.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 2, 2026
Pancreatic Cancer Cells Resist Cell Death Through HIF-2
Researchers studied how pancreatic cancer cells resist a type of cell death called ferroptosis. They found that a protein called HIF-2 helps these cells survive by increasing the production of a protective molecule called glutathione. This process involves several other proteins and pathways that help reduce damage to the cells.
Why it matters: This finding could help scientists understand how pancreatic cancer develops resistance to certain treatments and how to develop new therapies.
The study was conducted in a lab setting and its findings may not directly apply to human patients.
PreclinicalLab or cell studies. No human data yet.Est. completion: December 1, 2028
Preparing Patients for Pancreatic Cancer Surgery
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying a prehabilitation program for adults with pancreatic cancer before surgery. The program is multimodal, meaning it involves multiple approaches. The trial is currently recruiting participants.
Why it matters: This trial aims to improve patient outcomes by optimizing their physical and mental condition before undergoing pancreatic cancer surgery.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 1, 2026
Tensin Proteins May Play a Role in Pancreatic Cancer
Researchers studied tensin proteins in pancreatic cancer patients and found that TNS1 and TNS4 might be involved in the development of the disease. However, TNS2 and TNS3 did not seem to play a role. The study suggests that TNS1 could be a potential target for liquid biopsies.
Why it matters: This finding could help scientists better understand pancreatic cancer and potentially lead to new diagnostic or therapeutic approaches.
The study was based on a relatively small sample of 22 patients.
Animal StudyResults in animals only. May or may not apply to humans.Published: April 1, 2026
Pancreatic Cancer Mice Show Changes in Eating Habits
Researchers studied mice with pancreatic cancer to see how their eating habits changed over time. They found that the mice ate less and less frequently, and took longer to eat after meals. This suggests that the cancer may be affecting the mice's ability to regulate their appetite.
Why it matters: Understanding how pancreatic cancer affects eating habits could help researchers develop new treatments to address this symptom.
This study was conducted in mice and may not directly apply to humans.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 1, 2026
ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → Alone vs. ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → Plus Radiotherapy for Pancreatic Cancer
Researchers compared the effects of chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → alone versus chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → plus radiotherapy on patients with advanced pancreatic cancer. They found that the combination of chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → and radiotherapy improved disease control, but did not significantly affect survival rates. The study had a small sample size and more research is needed.
Why it matters: This finding may inform treatment decisions for patients with advanced pancreatic cancer and highlight the need for further research on the role of radiotherapy in this disease.
Efficacy
The disease control rate was 61.54% in the chemotherapy plus IMRT group.
The study had a small sample size of 70 patients from a single hospital.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 1, 2026
Rare Pancreatic Tumor Misdiagnosed as Cancer
Researchers used a special imaging test to examine a patient with abdominal pain. They found a tumor in the pancreas that was initially thought to be a cancer that had spread from another part of the body, but it turned out to be a different type of tumor. This case highlights the potential for misdiagnosis and the value of advanced imaging tests.
Why it matters: This finding may help doctors better understand how to diagnose and treat rare pancreatic tumors.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 1, 2026
Early Loss of Fat Tissue Linked to Poor Prognosis in Pancreatic Cancer
Researchers studied patients with unresectable pancreatic cancer and found that losing fat tissue in the first three months of treatment was associated with a poorer prognosis. This was more strongly linked to poor outcomes than changes in muscle or other fat tissue. The study suggests that monitoring fat tissue loss may help identify patients at higher risk.
Why it matters: This finding may help doctors identify patients who need closer monitoring or more aggressive treatment.
Efficacy
Greater preservation of SAT Δ% was associated with reduced mortality risk (HR per tertile step, 0.64; 95% confidence interval, 0.44-0.94)
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 1, 2026
New Protein Linked to Pancreatic Cancer Spread
Researchers studied pancreatic juice to find new biomarkersA measurable biological signal used to detect disease or predict treatment response.Click for full explanation → for pancreatic cancer. They found a protein called TBC1D23, which might help cancer spread to lymph nodes. In lab experiments, silencing this protein slowed cancer growth and spread.
Why it matters: This finding could lead to new ways to detect and treat pancreatic cancer, which is a difficult-to-treat disease.
This study was conducted in lab experiments and animal models.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: March 31, 2026
Rare Pancreatic Tumors Discovered in Postmenopausal Women
Researchers studied two cases of a rare type of tumor called solitary fibrous tumor (SFT) that occurred in the pancreas. The tumors were found in postmenopausal women who had no symptoms and were initially misdiagnosed. The researchers analyzed the tumors' characteristics and compared them to other types of tumors.
Why it matters: This finding may help doctors better diagnose and understand this rare type of tumor.
PreclinicalLab or cell studies. No human data yet.Est. completion: August 1, 2027
Investigating Lifestyle Changes in Pancreatic Cancer Patients
Researchers are studying how remote observation and nutrition guidance can support patients with pancreatic cancer. The trial is currently recruiting participants. The goal is to learn more about the effects of these interventions.
Why it matters: This trial aims to improve our understanding of how lifestyle changes can impact the lives of pancreatic cancer patients.
Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
Testing the Addition of Pembrolizumab, an ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCAGenes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →MutationsA change in DNA sequence that can drive cancer development.Click for full explanation →
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1Genes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →, BRCA2Genes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation → or PALB2 MutationA change in DNA sequence that can drive cancer development.Click for full explanation →
CA-4948 Added to Standard ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → to Treat Metastatic or Unresectable Pancreatic Cancer
